MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
40.93
+0.76
+1.89%
Opening 14:22 08/10 EDT
OPEN
39.96
PREV CLOSE
40.17
HIGH
41.24
LOW
39.90
VOLUME
103.05K
TURNOVER
--
52 WEEK HIGH
52.24
52 WEEK LOW
21.81
MARKET CAP
764.57M
P/E (TTM)
2.553
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RIGL last week (0803-0807)?
Weekly Report · 8h ago
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Kymera Therapeutics (KYMR) and Rigel (RIGL)
TipRanks · 4d ago
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts
Simply Wall St · 4d ago
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Seeking Alpha · 4d ago
Rigel Pharmaceuticals Balances Growth with Rising Costs
TipRanks · 4d ago
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Seeking Alpha · 4d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 5d ago
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.